Radicava (edaravone) is a drug that was approved by the U.S. Food and Drug Administration (FDA) to treat people with ALS in May of 2017. Dr. Jonathan Glass, Emory University, opens the presentation with a summary of the clinical trial data that led to the FDA approval of Radicava, and Darlene Sawicki, Massachusetts General Hospital, discusses the pros and cons of choosing Radicava, as well as details about obtaining the drug.
